Functional Skills
Acquisition Target Identification
Business Development
Forecasting / Projections
Gene Therapy
Go-to-market Strategy
Market Research
Marketing Strategy
Patient Experience
Product Strategy
Scenario Planning
Strategic Planning
Value Propositions Development
Brand Strategy
Commercial Strategy
Competitive Landscaping
Sector Experience
Life Sciences & Pharma
Fortune 500
Experience
Neumora Therapeutics, Inc.
Product Management / Strategy
Vice President, Commercial – New Product Planning
2/2023 - Present
First commercial hire; commercial lead for neuropsych and neurodegenerative portfolios and in support of corporate strategy.
• Provides commercial leadership and expertise on cross-functional Core Teams across portfolio of 7 clinical and preclinical programs.
• Established and leads competitive intelligence function; defines and executes on market research activities; incorporates market insights to define differentiated, commercially meaningful target product profiles; develops and manages commercial budgets, RFPs and contracting.
• Drives commercial activities for navacaprant (P3) including brand strategy, forecasting, brand name development, and external engagement.
See resume for addt'l responsibilities and accomplishments.
• Provides commercial leadership and expertise on cross-functional Core Teams across portfolio of 7 clinical and preclinical programs.
• Established and leads competitive intelligence function; defines and executes on market research activities; incorporates market insights to define differentiated, commercially meaningful target product profiles; develops and manages commercial budgets, RFPs and contracting.
• Drives commercial activities for navacaprant (P3) including brand strategy, forecasting, brand name development, and external engagement.
See resume for addt'l responsibilities and accomplishments.
ACCELERON PHARMACEUTICALS
Marketing
Senior Director, Global Strategic Marketing
8/2019 - 12/2022
Head ofearly commercial strategy and new product planning for internal programs in multiple TAs and in support of business development.
• Selected by management to build early commercial function including strategy, capabilities, and infrastructure; grew to 3 global commercial teams, 3 TAs, 6 new disease areas and multiple PC to clinical stage assets; established framework to evaluate pipeline and BD&L targets.
• Nominated by CCO to commercial leadership team; contributed to global commercial build-out and to establishing commercial operating model and core processes; and represented commercial on corporate-level strategic initiatives and on R&D working teams.
• Led cross-functional commercial teams for preclinical and clinical assets; executed early commercial activities including commercial assessments, KOL ad boards, external stakeholder initiatives and other cross-functional market shaping efforts; member of core team.
See resume for addt'l responsibilities and accomplishments.
• Selected by management to build early commercial function including strategy, capabilities, and infrastructure; grew to 3 global commercial teams, 3 TAs, 6 new disease areas and multiple PC to clinical stage assets; established framework to evaluate pipeline and BD&L targets.
• Nominated by CCO to commercial leadership team; contributed to global commercial build-out and to establishing commercial operating model and core processes; and represented commercial on corporate-level strategic initiatives and on R&D working teams.
• Led cross-functional commercial teams for preclinical and clinical assets; executed early commercial activities including commercial assessments, KOL ad boards, external stakeholder initiatives and other cross-functional market shaping efforts; member of core team.
See resume for addt'l responsibilities and accomplishments.
AVEXIS
Product Management / Strategy
Senior Director, ZOLGENSMA
5/2018 - 5/2019
Cross-functional Program Team Lead for ZOLGENSMAÒ, a transformative one-time gene therapy for Spinal Muscular Atrophy (SMA).
• Received FDA approval in May 2019; developed and led global asset strategy for ZOLGENSMAÒ IV/ IT; represented GPT to Leadership.
• Led LCM for ZOLGENSMAÒ in SMA Type 2/3 IT; presented strategy, positioning, and clinical plan to leadership; obtained endorsement.
• Drove global regulatory submissions and scenario planning to address label, managed access programs, and approval contingencies.
• Chaired Global Brand Team meeting; ensured global alignment on assets, messaging, and Gene Therapy educational initiatives.
• Led BD&L Neuromuscular Strategy and Assessment to direct licensing, acquisitions, and external research collaborations.
See resume for addt'l responsibilities and accomplishments.
• Received FDA approval in May 2019; developed and led global asset strategy for ZOLGENSMAÒ IV/ IT; represented GPT to Leadership.
• Led LCM for ZOLGENSMAÒ in SMA Type 2/3 IT; presented strategy, positioning, and clinical plan to leadership; obtained endorsement.
• Drove global regulatory submissions and scenario planning to address label, managed access programs, and approval contingencies.
• Chaired Global Brand Team meeting; ensured global alignment on assets, messaging, and Gene Therapy educational initiatives.
• Led BD&L Neuromuscular Strategy and Assessment to direct licensing, acquisitions, and external research collaborations.
See resume for addt'l responsibilities and accomplishments.
Shire
Marketing
Global Brand Lead, Immunology Marketing
1/2016 - 3/2018
Global Brand Lead for $100M portfolio in rare genetic disease with responsibility for on-market performance, global expansion, and LCM.
• Led marketing team in commercial strategy and brand plan development for alpha-1 portfolio (AralastÔ, GLASSIAÒ, and pipeline).
• Drove pre-launch of Phase 2/3 asset in acute GVHD including patient journey, KOL development, positioning, and messaging.
• Executed Transplant cross-franchise initiatives including market and KOL development, congress strategy, messaging, and budgeting.
• Defined, assessed, and prioritized LCM options and BD strategies to maximize the value of individual assets and portfolio.
See resume for addt'l responsibilities and accomplishments.
• Led marketing team in commercial strategy and brand plan development for alpha-1 portfolio (AralastÔ, GLASSIAÒ, and pipeline).
• Drove pre-launch of Phase 2/3 asset in acute GVHD including patient journey, KOL development, positioning, and messaging.
• Executed Transplant cross-franchise initiatives including market and KOL development, congress strategy, messaging, and budgeting.
• Defined, assessed, and prioritized LCM options and BD strategies to maximize the value of individual assets and portfolio.
See resume for addt'l responsibilities and accomplishments.
TAKEDA PHARMACEUTICALS
Product Management / Strategy
Director, Global Therapeutic Area Strategy
1/2012 - 2/2015
Global Strategy Lead for $2.7B Global Gastroenterology Franchise achieving 24% yoy franchise growth.
• Developed TA strategy that secured GI as core focus area; provided commercial expertise; set goal of industry leadership by 2020.
• Led new product planning efforts to develop 'white paper' and assess BD assets; invested in 2 new areas (celiac and gastroparesis).
• Drove global GI portfolio strategy including value prop, patient segmentation, product positioning and regional collaborations
• Spearheaded development of GI Strategy & Future Vision presentation for inaugural Investor Day (>100 institutional investors).
• Developed TA strategy that secured GI as core focus area; provided commercial expertise; set goal of industry leadership by 2020.
• Led new product planning efforts to develop 'white paper' and assess BD assets; invested in 2 new areas (celiac and gastroparesis).
• Drove global GI portfolio strategy including value prop, patient segmentation, product positioning and regional collaborations
• Spearheaded development of GI Strategy & Future Vision presentation for inaugural Investor Day (>100 institutional investors).
AbbVie
Corporate Strategy & Development
Senior Manager, Global Licensing & New Business Development
6/2007 - 11/2011
Licensing & Business Development professional driven to set strategy and execute transactions for novel Immunology and Oncology assets.
• Executed novel Oncology and Immunology licensing deals; led evaluation and negotiations; presented recommendations to C-suite.
• Transacted Oncology licensing deal for novel ADC technology; leveraged solid tumor knowledge; led investment process.
• Developed Immunology Licensing Strategy; led all aspects of investment process; Therapeutic Exec Committee member.
• Awarded "Most Admired Corporate Dealmakers Award" as Abbott team member in 2008, 2009, and 2010 from The Deal.
• Executed novel Oncology and Immunology licensing deals; led evaluation and negotiations; presented recommendations to C-suite.
• Transacted Oncology licensing deal for novel ADC technology; leveraged solid tumor knowledge; led investment process.
• Developed Immunology Licensing Strategy; led all aspects of investment process; Therapeutic Exec Committee member.
• Awarded "Most Admired Corporate Dealmakers Award" as Abbott team member in 2008, 2009, and 2010 from The Deal.
Genentech
Marketing
Market Planning Manager, AVASTINÒ Franchise Marketing
9/2004 - 5/2007
Commercial Development Lead for AVASTINÒindications outside of breast, lung, and colorectal cancers and for pan-tumor initiatives.
• Led AVASTINÒ lifecycle management process; resulting in 8 new approved oncology clinical programs in solid tumor and heme.
• Advanced go-to-market strategies for Franchise development indications (~20 new oncology indications preclinical to Phase 3).
• Developed AVASTINÒ Pan-Tumor HCP marketing campaign; executed market research and worked with agency to create visuals.
See resume for addt'l responsibilities and accomplishments.
• Led AVASTINÒ lifecycle management process; resulting in 8 new approved oncology clinical programs in solid tumor and heme.
• Advanced go-to-market strategies for Franchise development indications (~20 new oncology indications preclinical to Phase 3).
• Developed AVASTINÒ Pan-Tumor HCP marketing campaign; executed market research and worked with agency to create visuals.
See resume for addt'l responsibilities and accomplishments.
Venture Capital Group
Corporate Strategy & Development
ABN AMRO PRIVATE EQUITY Associate
1/2000 - 1/2002
• Sourced, analyzed and recommended prospective investments of $3-$7M in life sciences and healthcare technology.
Life Sciences Management Consulting
Management Consulting
APM/CAP GEMINI ERNST & YOUNG Consultant
1/1996 - 1/2000
• Led numerous client engagements to evaluate and execute strategic growth options and identify operational efficiencies.
See resume for addt'l responsibilities and accomplishments.
See resume for addt'l responsibilities and accomplishments.